Montelukast for Acute Bronchiolitis and Postbronchiolitis Viral Induced Wheezing
Launched by HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES · Jun 8, 2011
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
All the patients will be evaluated at the baseline, during hospitalization (daily) and at 2 months and 6 months after starting the intervention.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • infant in 3-12 months of age with first episode of wheezing or bronchiolitis
- • written informed consent by parents
- Exclusion Criteria:
- • Previous wheezing episode or confirmed asthma or bronchiolitis
- • recent bronchodilator use
- • immune deficient
- • immunosuppressive drug use
- • croup or pneumonia diagnosis
- • loss of follow up
About Hormozgan University Of Medical Sciences
Hormozgan University of Medical Sciences is a leading academic institution dedicated to advancing healthcare through innovative research and education. Located in Iran, the university focuses on enhancing medical knowledge and practices in the region by conducting high-quality clinical trials. With a commitment to improving patient outcomes, Hormozgan University fosters collaboration among healthcare professionals, researchers, and students, ensuring the development of effective therapies and interventions. The institution is recognized for its rigorous ethical standards and adherence to regulatory guidelines, making it a trusted sponsor for clinical research initiatives that aim to address critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bandar Abbas, Hormozgan, Iran, Islamic Republic Of
Patients applied
Trial Officials
Ali Asghar Parhiz, Resident
Principal Investigator
Hormzgan University of Medical Sciences (HUMS)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials